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Abstract
Aims/hypothesis In insulin-secreting cells, activation of the
c-Jun NH2-terminal kinase (JNK) pathway triggers apoptosis.
Whereas JNK1 and JNK2 are ubiquitously produced, JNK3
has been described exclusively in neurons. This report aims to
characterise the expression and role in apoptosis of the three
JNK isoforms in insulin-secreting cells exposed to cytokines.
Methods Sections of human and mouse pancreases were
used for immunohistochemistry studies with isoform-
specific anti-JNK antibodies. Human, pig, mouse and rat
pancreatic islets were isolated by enzymatic digestion and
RNA or protein extracts were prepared. RNA and protein
levels were determined by quantitative RT-PCR and
western blotting respectively, using JNK-isoform-specific
primers and isoform-specific antibodies; activities of the
three JNK isoforms were determined by kinase assays
following quantitative immunoprecipitation/depletion of
JNK3. JNK silencing was performed with small interfering
RNAs and apoptotic rates were determined in INS-1E cells
by scoring cells displaying pycnotic nuclei.
Results JNK3 and JNK2 mRNAs are the predominant
isoforms expressed in human pancreatic islets. JNK3 is
nuclear while JNK2 is also cytoplasmic. In INS-1E cells,
JNK3 knockdown increases c-Jun levels and caspase-3
cleavage and sensitises cells to cytokine-induced apoptosis;
in contrast, JNK1 or JNK2 knockdown is protective.
Conclusions/interpretation In insulin-secreting cells, JNK3
plays an active role in preserving pancreatic beta cell mass
from cytokine attacks. The specific localisation of JNK3 in
the nucleus, its recruitment by cytokines, and its effects on
key transcription factors such as c-Jun, indicate that JNK3
is certainly an important player in the transcriptional control
of genes expressed in insulin-secreting cells.
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Abbreviations
GFP Green fluorescent protein
GST Glutathione S-transferase
HaCaT Human keratinocyte
HEK Human embryonic kidney
IB1 Islet-brain 1
IB2 Islet-brain 2
JIP c-Jun-NH2-terminal kinase interacting protein
JNK c-Jun-NH2-terminal kinase
PDX-1 Pancreatic and duodenal homeobox 1
REST Transcriptional repressor element 1 silencing
transcription factor
siRNA Small interfering RNA
Introduction
Apoptosis of insulin-secreting cells is a major event leading
to insulin depletion in type 1 diabetes and also contributing
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to islet transplantation failure [1–4]. The mechanisms
leading to apoptosis have been partly deciphered and
involve, among other intracellular pathways, p38 mitogen-
activated protein kinase [5], nuclear factor kappa B [6],
signal transducer and activator of transcription 1 [7] and
activation of the stress-activated proteins c-Jun NH2-
terminal kinases (JNKs) [3, 8]. Three JNK isoforms
(JNK1, JNK2 and JNK3) encoded by three distinct genes
have been identified [9]; JNK1 and JNK2 are ubiquitously
produced, but JNK3 is essentially restricted to neurons [10,
11]. The role of JNK3 in neuronal excitotoxicity and
cerebral ischaemia has been particularly well studied [12–
14]; earlier reports indicated that JNK3 was the main pro-
apoptotic JNK-isoform in neurons, but more recent data
appear to also implicate JNK2 [15, 16].
Insulin-secreting cells and neurons share a number of
genes that are predominantly or exclusively expressed in
both tissues, e.g. the genes encoding: neuronal cell
adhesion molecule, N-cadherin [17], neuron specific eno-
lase [18], glutamic acid and glutamate decarboxylase [19],
and islet-brain 1 (IB1) and 2 (IB2) (c-Jun-NH2-terminal
kinase interacting protein [JIP] 1 and 2 respectively) [20,
21]. These characteristics probably originate from a
common developmental lineage [22]. To date, functional
characterisation of the JNK brain-specific isoforms in
pancreatic islets has not been performed.
In this study we characterised the expression profile of the
three JNK family members in human, pig, mouse and rat
pancreatic islets, as well as their sub-cellular localisation and
their activities following cytokine treatment. Comparative
studies using small interfering RNAs (siRNAs) in rat cell lines
were performed to determine the contribution of individual
JNK isoforms in cytokine-mediated beta cell death.
Methods
Cell and islet culture preparations Pancreas and islet
specimens were prepared from four different deceased
human multiorgan donors or from pigs that had been killed.
In each case, the purity of human or pig islet preparations
was >70%. The human donor’s exemption code from the
Institutional Review Board is 0307M50821. Animal experi-
mentation conformed to the Guide for Care and Use of
Laboratory Animals, formulated by the National Research
Council, 1996, and Swiss law on animal protection, and
was authorised by the Veterinarian Office of Canton de
Vaud (Lausanne, Switzerland).
Adult male rat (Wistar) pancreases were digested with
collagenase solution, the fragmented tissue was washed and
collected by centrifugation at 300 g and islets were
separated on Ficoll density gradients. Human and pig islets
were kindly provided by B. Hering (Diabetes Institute,
University of Minnesota, MN, USA) and islet isolation was
performed as previously described [3, 8]. Purified islets
were cultured for 2 days in CMRL-1066 (Mediatech,
Herndon, VA, USA) supplemented with 10% (vol./vol.)
fetal bovine serum (Mediatech). The rat insulin-secreting
beta cell line (INS-1E) was maintained in RPMI 1640
medium supplemented with 10% (vol./vol.) fetal bovine
serum, 10 mmol/l HEPES, pH 7.4, 1 mmol/l sodium
pyruvate and 50 μmol/l β-mercaptoethanol in 5% CO2
humidified atmosphere at 37°C.
Cell lysis and western blotting Cells or fresh tissues were
homogenised in cold lysis buffer as described previously
[3, 8] and the protein extracts recovered by centrifugation at
20,000 g. Equal quantities of total protein lysates were
resolved by SDS-PAGE and electroblotted on to polyvinyl-
idene fluoride membranes. The blots were probed overnight
with primary antibodies against: JNK1, p53 (1:500; Santa
Cruz Biotechnology, Santa Cruz, CA, USA); and JNK2,
JNK3, c-Jun, JunB, phospho-c-Jun or cleaved caspase-3
(1:1,000; Cell Signaling Technology, Danvers, MA,
USA). Equal protein loading was determined by blotting
membrane against tubulin (1:5,000; Sigma-Aldrich, Buchs,
Switzerland). Anti-rabbit or mouse horseradish peroxidase-
conjugated secondary antibodies were used to detect
protein bands with enhanced chemiluminescence reaction
system (Amersham Pharmacia, Biotech Europe, Dübendorf,
Switzerland).
Real-time polymerase chain reaction (RT-PCR) RNA was
extracted from tissues or cells using a commercial kit
(RNAeasy Mini-kit; Qiagen, Basel, Switzerland) and 1 μg
was used for reverse transcription to cDNA with Super
script II enzyme (Gibco Invitrogen, Basel, Switzerland).
Gene expression was measured by RT-PCR (Light-Cycler
PCR System, Roche, Basel, Switzerland) as recommended
by the supplier. Quantitative PCR reactions were performed
in Master Mix SyBr Green (4 mmol/l; Master Mix;
Eurogentec, Liege, Belgium) using 0.5 μmol/l primer mix
(Electronic supplementary material [ESM] Table 1) and
2 μl RT product in a total of 20 μl.
Quantitative analysis of mRNA expression using restriction
endonucleases Degenerate primers (ESM Table 1) were
designed to amplify the three human JNK mRNAs (JNK1,
JNK2, JNK3 [also known as MAPK8, MAPK9 and
MAPK10 respectively]) simultaneously and with high
efficiency by Light-Cycler. We verified that this set of
primers was equally effective in amplifying each JNK
isoform by using separate plasmids coding for human
JNK1, JNK2 or JNK3 genes in real-time PCRs. PCR
products were purified, cloned into pGEM-t Easy Vector
(Promega, Wallisellen, Switzerland) and produced by
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bacterial transformation. We screened 60 positive clones by
PCR and determined the distinction between the three
isoforms of JNK mRNA by restriction digest. Three
endonuclease enzymes (PstI, EcoRV and HindIII) were
used to distinguish JNK1, JNK2 and JNK3 cDNAs
respectively, on agarose gels.
siRNAs design and cell transfection Small interfering RNA
duplexes against Jnk1, Jnk2, Jnk3 [23] and the green
fluorescent protein (GFP) were designed (ESM Table 2)
and submitted to BLAST search to ensure their specificity
toward the target mRNAs. siRNAs were synthesised by
Mycrosynth (Balgach, Switzerland).
Rat INS-1E cells were seeded in six-well plates and
incubated overnight in antibiotic-free medium. siRNA
duplexes targeting Jnk1, Jnk2 and Jnk3 were mixed with
Lipofectamine2000 reagent (10 μg/ml) according to the
manufacturer’s instructions (Invitrogen, Basel, Switzerland).
siRNA–lipofectamine complexes were added to the cells and
incubated for 2 days. Cells were exposed to a cytokine
cocktail (R&D Systems, Minneapolis, MN, USA) of rat
IL-1β (10 ng/ml), mouse TNFα (25 ng/ml) and rat IFNγ
(150 ng/ml) for 24 h.
Immunohistochemical and immunocytochemical staining
procedures Immunohistochemistry was performed on
paraffin-embedded adult human and mouse pancreatic
sections (5µm thick) collected on polylysine-coated slides.
Paraffin sectionswere rehydrated, processed for antigen retrieval
and pre-incubated with PBS containing 15% (vol./vol.) donkey
serum for 1 h.
For immunocytochemistry, INS-1E cells were fixed for
15 min in paraformaldehyde 4% (wt/vol.) on ice and then
pre-incubated (0.3% [vol./vol.] Triton X-100, 15% [vol./vol.]
donkey serum in PBS) for 1 h. Primary antibodies were
incubated overnight at 4°C after dilution in 1.5% (vol./vol.)
donkey serum at the following concentrations: 1:100 rabbit
anti-JNK3 (Upstate, Lake Placid, NY, USA), 1:50 mouse
anti-JNK2 (Santa-Cruz Biotechnology, Santa Cruz, CA,
USA) and 1:500 guinea pig anti-insulin (Dako, Carpinteria,
CA, USA). After extensive washes in PBS, the sections were
incubated for 2 h at room temperature in the appropriate
secondary biotinylated donkey anti-mouse or donkey anti-
rabbit or donkey anti-guinea pig antibody (Jackson Immu-
noresearch, West Grove, PA, USA) diluted 1:500 in PBS.
The sections were thoroughly rinsed in PBS and incubated
for 2 h at room temperature with streptavidin–biotin–
peroxidase complex (Vectastain ABC kit, Vector Laborato-
ries, Burlingame, CA, USA). Immunolabelling was revealed
after three washes in PBS using 2,3′ diaminobenzidene as
substrate diluted 1:10 in buffer according to the manufac-
turer’s instructions (Roche). Sections were then dehydrated
and mounted in Eukitt (O. Kindler, Freiburg, Germany). The
specificity of the immunostaining was confirmed by omis-
sion of the first antibody or use of preadsorption of primary
antibodies with the immunising peptide. Images were
acquired by optical microscopy.
Immunoprecipitation and JNK kinase assays Pre-cleared
protein extracts (300 μg) were mixed overnight at 4°C with
1 μg of anti-JNK3 antibody. Protein-G agarose beads
(50 μl; Calbiochem, San Diego, CA, USA) were then
added for an additional incubation of 4 h. Immobilised
protein–antibody complexes were washed three times in
cold PBS, collected by centrifugation at 2,000 g and lysed
in kinase buffer (20 mmol/l HEPES pH 7.5, 20 mmol/l
β-glycerophosphate, 10 mmol/l MgCl2). Supernatant frac-
tions were controlled for potentially remaining JNK3 by
western blotting. Isoform-specific JNK activities were deter-
mined by in vitro reactions using glutathione S-transferase
(GST)–c-Jun (amino acids 1–79) beads mixed to [γ-33P]ATP
(Amersham Biosciences, Little Chalfont, UK). The kinase
reactions were performed for 30 min at 30°C and stopped
by adding SDS sample buffer (100 mmol/l Tris, pH 6.8,
2% [wt/vol.] SDS, 10% [vol./vol.] glycerol, 5% [vol./vol.]
2-β-mercaptoethanol, 0.25% [wt/vol.] bromophenol blue).
Phosphorylation of substrate proteins was detected by
autoradiography of dried gels (BioMax MS films; Kodak,
GE Healthcare, Amersham Biosciences, Little Chalfont,
UK).
Apoptosis assay Apoptosis was determined by scoring cells
displaying pycnotic nuclei stained with the DNA-binding
dyes Hoechst 33342 (10 μg/ml; Sigma-Aldrich, St Louis,
MO, USA) and propidium iodide (5 μg/ml; Sigma-Aldrich,
St Louis, MO, USA), as described previously [24], and
visualised under an inverted fluorescence microscope.
Statistics All experiments reported were performed a
minimum of three times (i.e. n=3–9 for all data). Data are
given as means±SEM. Statistical analysis of multiple
comparisons was determined by one-way ANOVA (post
hoc comparisons, Scheffe’s test). The differences found
between the experimental groups were considered statisti-
cally significant at p<0.05 or p<0.01.
Results
JNK3 is highly produced in pancreatic islets To determine
in situ levels of the JNK3 protein in pancreatic islets, we
performed immunohistochemistry studies on human and
mouse pancreas sections using specific antibodies against
JNK3 and insulin. Human (Fig. 1a) and mouse (Fig. 1a)
pancreas sections were stained with haematoxylin and
eosin. JNK3-positive cells (Fig. 1a) were also positive for
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insulin (Fig. 1a). While insulin staining was mostly
cytoplasmic, JNK3 was nuclear. The specificity of the
JNK3 antibody was ascertained by western blotting using
whole-brain protein extracts originating from Jnk1, -2 or -3
knockout mice (Fig. 1b).
We next examined by western blot analysis the levels of
JNK3 in different tissues. The blots revealed that JNK3
occurs in high levels in human and pig islets, but was not
detected in either of the whole-pancreas species (Fig. 1c).
In the rat, JNK3 production was restricted to the brain and
Fig. 1 Analyses of protein production, with a immunohistochemistry
analysis using haematoxylin and eosin staining (H&E) of pancreatic
tissue sections as shown, JNK3 immuno-staining of representative
pancreatic islet cells (arrows), insulin immuno-staining (INS) of
representative pancreatic islet cells and negative controls (CTL).
Original magnification, ×20; scale bar, 50 μm. b The specificity of the
antibody was tested by western blotting using whole-brain protein
extracts derived from wild-type (WT) and Jnk1, Jnk2 or Jnk3
knockout mice. c–e Western blot analysis of protein extracts prepared
from different species and used in experiments with monoclonal anti-
JNK3 and anti-tubulin antibodies, i.e. in c whole pancreas and isolated
islets from human or pig, d rat tissues and e different insulin-secreting
(INS-1E, βTC3, MIN6) and non-secreting (HaCaT, HEK293T) cell
lines. Protein extracts from mouse and rat whole brain were used e as
positive controls for JNK3 detection. Data are representative of three
independent experiments (n=3)
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pancreatic islets (Fig. 1d), whereas JNK1 and JNK2 were
ubiquitously produced at similar levels in the tissues tested
(data not shown).
In insulin-producing cell lines, production of JNK3 was
restricted to the rat beta cell line INS-1E; JNK3 was not
detected in mouse βTC3 and MIN6 cell lines (Fig. 1e).
Antibody specificity was confirmed using protein extracts
from human keratinocyte (HaCaT) and human embryonic
kidney (HEK)293T cell lines, which do not produce JNK3;
protein extracts from mouse or rat brain were used as
positive controls for JNK3 detection (Fig. 1e).
Quantitative analysis of JNK1, JNK2 and JNK3 mRNA
levels in pancreatic islets To determine the endogenous
levels of JNK1, JNK2 and JNK3 mRNA in different
tissues, quantitative real-time PCR (Light-Cycler) was
performed with primers specific for each JNK isoform
(Fig. 2a). In human purified islets, JNK3 mRNA was
expressed at levels similar to those found in the brain. A
strong reduction in JNK3 mRNA expression was observed
after 2 days of culture (Fig. 2b). No amplification product
was obtained in these conditions from the other tissues
tested and in particular from whole pancreas. JNK1 and
JNK2 transcripts were detected in all examined human
tissues with predominant expression of JNK1 mRNA in the
brain and lower levels in pancreatic islets (Fig. 2b). No
major alteration of JNK1 or JNK2 mRNA levels was
observed in purified vs cultured islets. Similar observations
were noted for rat and mouse tissues (Fig. 2c).
To determine the relative levels of JNK1, JNK2 and
JNK3 mRNA in isolated human islets, we used degenerate
primers to amplify all three mRNAs simultaneously. We
confirmed that this set of primers was equally effective in
amplifying each JNK gene separately (data not shown).
PCR products were then cloned and analysed by enzymatic
digestion to allow discrimination of the respective JNK
isoforms. JNK2 and JNK3 isoforms (EcoRV and HindIII
fragments, respectively) represented 45% each of the total
JNK clones analysed, while 10% of the clones were of
Fig. 2 mRNA expression analyses. a Isoform-specific primers were
tested by PCR using plasmids (1 ng) encoding JNK1, JNK2 and JNK3
cDNAs. The resulting PCR products were resolved on 1% agarose
gels containing ethidium bromide and visualised by ultra-violet
fluorescence. b Total RNA was isolated from human and c murine
tissues, and reverse-transcribed to cDNA before PCR amplification
(Light-Cycler). The sample RNAs were normalised to tubulin
(Tuba1a) mRNA (internal control); the relative levels of the mRNA
for each JNK gene were set to 100% in the brain samples of each
species. ‘Purified’ or ‘cultured’ indicates human islets immediately
after the isolation process or 2 days after culture. White bars, JNK1;
grey bars, JNK2; black bars, JNK3 (b). c Black bars, rat; white bars,
mouse. Data are the mean of n=4 (b) or n=3 (c) independent
experiments. d Relative amounts of JNK isoforms in human
pancreatic islets. Degenerate primers were used to simultaneously
amplify the genes encoding all three JNK isoforms. PCR products
were then cloned into the pGEM-T vector. Sixty clones were screened
by PCR and the identity of each JNK gene was determined by
enzymatic digestion. PstI, EcoRVand HindIII were used to distinguish
JNK1, JNK2 and JNK3, respectively. DNA fragments were analysed
on agarose gels stained with ethidium bromide. Data are representative
of three independent experiments
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JNK1 origin (Fig. 2d). Thus JNK2 and JNK3 represent the
two most highly expressed JNK isoforms in human
pancreatic islets.
JNK3 is a component of a functional signalling pathway
activated by cytokines To address whether JNK3 is activated
after exposure to cytokines, INS-1E cells were treated with
IL-1β, TNFα and IFNγ individually or in combination (Cyto-
Mix) for 1 h. JNK3 was then quantitatively immuno-
precipitated from the protein extracts; we verified by western
blotting that following JNK3 immuno-precipitation, JNK3 was
absent from the supernatant fractions and that no JNK1/2 could
be detected in the pellets (not shown). JNK1/2 (supernatant
fractions) vs JNK3 (pellets) activity was assessed by in vitro
kinase assays using GST-c-Jun as a substrate. All three isoforms
of JNK were potently activated by IL-1β and to a lesser extent
by TNFα; in particular, JNK3 appeared to be activated to a
similar extent to JNK1 and JNK2 together (Fig. 3). This
indicates that JNK3 can be potently activated by cytokines in
beta cells.
JNK3 is nuclear whereas JNK2 is both cytoplasmic and
nuclear Immunocytochemistry studies were carried out to
determine the sub-cellular localisation of JNK3 and JNK2
in INS-1E cells. As shown in Fig. 4a, JNK2 was detected in
both cytoplasmic and nuclear compartments, while JNK3
was restricted to the nucleus (see also Fig. 1a). The
specificity of the JNK3 (Fig. 1b) and JNK2 (Fig. 4b)
antibodies was ascertained by western blotting using
whole-brain protein extracts originating from Jnk1, -2 or
-3 knockout mice respectively.
Knockdown of JNK3 in INS-1E cells results in higher c-Jun
levels The different intracellular (nuclear vs nuclear/cyto-
plasmic) localisations of JNK3 and JNK2 in INS-1E cells
suggest that these two isoforms might differentially control
the cellular responses elicited by the same input stresses. To
investigate whether the individual JNK isoforms might
differentially transduce cytokine signalling, INS-1 cells
were transfected with siRNAs specific for the JNK3,
JNK2 and JNK1 isoforms, while siRNA against GFP
(siGFP) was used as a negative control. JNK3 knockdown
decreased JNK3 protein levels up to 90% with little if any
effect on JNK1 or JNK2 (Fig. 5a). JNK1 and JNK2
knockdown were also performed and showed a specific
Fig. 3 Kinase activity analyses. INS-1E cells were exposed to the
cytokines IL-1β, TNFα, or IFNγ individually or in combination
(Cyto-Mix) for 1 h and protein extracts were then prepared. Pre-
cleared extracts (300 μg) were used for JNK3 immuno-precipitation
with protein A-agarose beads. The supernatant fractions (p-JNK1/2) or
the immuno-complexes (p-JNK3) were tested in in vitro kinase
reactions with GST–c-Jun as a substrate and [γ-33P]ATP. Part of the
supernatant fractions was used for western blot analysis to ascertain
equal loading using the anti-JNK1/2 antibody. Data shown are the
mean of three independent experiments
Fig. 4 a Subcellular localisation analyses in INS-1E cells. Immuno-
cytochemical staining localised JNK3 in the nucleus exclusively,
while JNK2 staining appeared in the cytoplasm, with a nuclear
staining component that cannot be excluded. Negative controls (CTL)
used non-immunised rabbit serum. Original magnification: ×10 and
×20 on left and right, respectively; scale bar, 50 μm. b Specificity of
the JNK2 antibody was tested by western blotting using whole-brain
protein extracts derived from Jnk1, Jnk2 or Jnk3 knockout mice. WT,
wild-type
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reduction of JNK1 (85%) and JNK2 (90%), respectively,
with little if any effect on the other JNK isoforms (data not
shown and Fig. 6a).
Western blot experiments indicate that JNK3 knockdown
increased the protein level of c-Jun; cytokines had a similar,
but more pronounced, effect on c-Jun induction (Fig. 5b).
Combined JNK3 knockdown and cytokines resulted in an
even higher phosphorylation of c-Jun than in each of the
separate conditions (Fig. 5c). In contrast, JNK2 knockdown
had no detectable effect on levels of c-Jun production in the
basal state (Fig. 5b). Both, JNK1 or JNK2 deficiency
decreased c-Jun phosphorylation induced by cytokines
(Fig. 5c).
Previous studies have shown that the activator protein-1
component JunB is upregulated by cytokines [25, 26].
Cytokines increased JunB levels as expected; JNK1 and to
a lesser extent JNK3, but not JNK2 knockdown appeared to
decrease cytokine-induced JunB upregulation (Fig. 5c).
JNK3 knockdown increases apoptosis To determine the
role of the different JNK isoforms in cytokine-induced
apoptosis, INS-1E cells were transfected with the siRNAs
targeting the different JNK genes and were exposed for
24 h to the cytokine cocktail. JNK2 or JNK1 knockdown
significantly protected beta cells against cytokine-induced
apoptosis and improved beta cell viability by 60 and 40%
respectively compared with control siGFP-transfected cells
(Fig. 6a). In contrast, JNK3 knockdown strongly enhanced
the effect of cytokines on apoptosis. As control, similar
results were obtained when using a different siRNA (si3II)
against Jnk3 [23] (Fig. 6a). The pro-apoptotic effect of
JNK3 knockdown was associated with an increase in
caspase-3 cleavage (as evidenced by the appearance of a
19 kDa fragment) at basal or under stress conditions (Cyto-
Mix) (Fig. 6b). A similar pattern of cleaved caspace-3 was
observed with the second siRNA (si3II) against Jnk3 (data
not shown). In contrast, JNK1 or JNK2 knockdown were
able to block caspase-3 activation. None of these conditions
appeared to affect p53 stability (Fig. 6b).
These data were further sustained by transfecting the
siRNAS in βTC-3 cells. Because these cells lack JNK3 (see
Fig. 1e), JNK3 knockdown was not expected to have any
effect on viability of these cells. Indeed, JNK3 knockdown
did not increase apoptosis compared with the siGFP control
under cytokine treatments (data not shown).
Discussion
We describe here the content of JNK3 in pancreatic islets,
where it is found at levels similar to those measured in the
brain. Our data indicate a protective role of JNK3 against
cytokine-induced beta cell death. Whereas knockdown of
JNK1 or JNK2 is anti-apoptotic, JNK3 knockdown poten-
tiates cell death in INS-1E cells. Both effects correlate well
with the levels of and phosphorylation of c-Jun, which are
elevated in the absence of JNK3 and reduced in the absence
of the JNK1 or JNK2 isoforms.
Fig. 5 a Transfection efficiency of siRNAs. INS-1E cells were
transiently transfected with Jnk3 siRNA (si3) at different doses as
shown using lipofectamine 2000. siGFP (120 pmol) was used as a
control. JNK3 protein knockdown was tested by western blotting
using an anti-JNK3 antibody; anti-JNK1 and anti-JNK2 antibodies
were used to assess the specificity of the assay. Equal protein loading
was determined with a tubulin antibody. b, c Transfected cells (si3, si2
and si1) were treated with or without cytokines (Cyto-Mix) for 1 h and
extracted proteins were resolved by western blotting to determine
c-Jun (b) and JunB or phospho-c-Jun (P-c-Jun) (c) levels. Equal
protein loading was verified with an anti-tubulin antibody. Optical
density for each protein band was quantified by densitometric
scanning; ratios normalised to tubulin (controls set to 1) are indicated.
Data are representative of n=4 (a) or n=3 (b, c) independent
experiments
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The phenotype of JNK3 knockdown is similar to that
observed with JunB knockdown, which also increases
apoptosis [26]. Interestingly, we observed a JunB decrease
in cells lacking JNK3. The question of whether JunB is a
major determinant of apoptosis in JNK3-deficient insulin-
secreting cells undoubtedly warrants further investigation.
However, the situation is further complicated in JNK1 or
JNK2 knockdown, where increased levels of JunB corre-
lates with protection (JNK2), but not with JNK1 (decreased
apoptosis and decreased JunB levels).
In other cell types including fibroblasts, it has been
shown that inactive JNK targets c-Jun to ubiquitination,
whereas activation of JNK improves c-Jun stability [27,
28]. Conflicting studies, however, have shown that JNK-
mediated phosphorylation of c-Jun accelerates its ubiquiti-
nation in T cells [29, 30]. In fibroblasts and in neurons,
JNK is usually observed essentially in the cytoplasm, with a
fraction of it translocating to the nucleus following
activation [31, 32]. We observed very pronounced differ-
ences in the intracellular distribution of JNK2 (nuclear and
cytoplasmic) vs JNK3, with JNK3 being essentially
nuclear. Thus, insulin-secreting cells are clearly distinct
from other cell types in that they have high amounts of JNK
(JNK3) in the nucleus at basal states.
It is not clear whether the main differences between
JNK3 and JNK2 or JNK1 knockdown that we observed are
related to the levels of each kinase as such or potentially to
the specific intracellular localisation of JNK3 vs JNK2.
However, the importance of the intracellular localisation of
the different JNK isoforms towards apoptosis has already
been addressed [32–34]: in neurons, blockage of nuclear
JNKs appears neuroprotective, whereas blocking cytoplas-
mic JNKs has a strong pro-apoptotic activity [34, 35]. It
should, however, be noted that in these experiments,
‘cytoplasmic’ blockade of JNK resulted in depletion from
the nucleus of JNKs, which bind to the cytosolic IB1/JIP-1
protein that is exogenously expressed in the cytoplasm
(J. Puyal, Department of Cellular Biology and Morphology,
University of Lausanne, Lausanne, Switzerland, personal
communication). A similar observation had already been
made by Dickens, who showed that expression of IB1/JIP-1
‘traps’ JNK in the cytoplasm, depleting the nuclear
compartment [35]. Thus, these and our data indicate that
depletion of nuclear JNK is toxic, therefore suggesting that
nuclear JNK has a protective role in neurons and insulin-
secreting cells.
The effects of JNK3 on apoptosis might be linked to the
control of key factors directly contributing to the apoptotic
machinery and controlled by c-Jun, such as the Fas-ligand
[36, 37] or the gene encoding p53 [38]; we did not detect
any effect of JNK3 knockdown on p53 expression in our
conditions. However, the effect might also be indirect.
Indeed, the JNK–c-Jun signalling pathway is known to
control expression of the insulin promoter by repressing
cAMP-induced insulin transcriptional activity [39]. More-
over, pancreatic and duodenal homeobox 1 (PDX-1), an
important activator of the insulin promoter, is translocated
from the nucleus to the cytoplasm of pancreatic beta cells in
response to oxidative stress [40, 41]. Dominant negative
forms of JNK inhibit oxidative stress-induced PDX-1
translocation, suggestive of another way by which JNK,
and in particular JNK3, might regulate activity of the
insulin promoter. Given the known protective role of
Fig. 6 Effects of JNK1, JNK2 and JNK3 knockdown on cytokine-
mediated apoptosis. a INS-1E cells were transfected with the siRNAs
described above, i.e. Jnk1 (si1), Jnk2 (si2) and Jnk3 (si3) or siGFP, for
48 h. Transfected cells were then treated for 24 h with or without the
cytokine cocktail (Cyto-Mix). JNK1, JNK2 and JNK3 protein knock-
downs were tested by western blot using specific antibodies and
protein normalisation (tubulin) as above (Fig. 5a). Cell apoptosis was
determined by scoring pycnotic nuclei visualised by Hoechst and
propidium iodide dyes under a fluorescence microscope. *p<0.05 or
**p<0.01 for Mix-si3/si3II vs Mix-siGFP, for Mix-si2 vs Mix-siGFP
and for Mix-si1 vs Mix-siGFP. White bars, basal; grey bars, siRNA;
black bars, siRNA-cytokines. b Whole cell lysates were analysed by
western blotting for cleaved caspase-3 (19 kDa fragment) and p53
expression. Optical density for each protein band was quantified by
densitometric scanning; ratios normalised to tubulin (controls set to 1)
are indicated. Data are representative of n=3 independent experiments
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insulin acting in an autocrine manner on insulin-secreting
cells, JNK3 might potentially control apoptosis through the
regulation of insulin expression. Indeed, JNK3 knockdown
may affect insulin expression (data not shown).
Pancreatic beta cells and neurons share many phenotypic
traits such as the expression of neurotrophin receptors [42]
or neuron-specific factors [17–21]. These similarities may
be partly explained by the action of a key transcriptional
repressor known as ‘transcriptional repressor element 1
silencing transcription factor’ (REST/NRSF). REST acts as
a transcriptional repressor that controls the transcription of
neuronal genes in non-neuronal tissues, but is not produced
in neurons and endocrine pancreas; accordingly, most of its
target genes are highly expressed in these two cell types,
because they lack REST expression [43–45]. Genes
targeted by REST encode neuronal genes expressed in beta
cells, such as connexin 36, synaptophysin, secretogranin II
and neuronal receptors like glutamate receptor 2 and brain-
derived neurotrophin factor [45], as well as IB1 [20] or IB2
[21] transcription factors and adhesion molecules [17]. The
regulatory region of the JNK3 gene contains a potentially
functional repressor element-1 that might interact with
REST (http://bioinformatics.leeds.ac.uk/group/online/
RE1db/re1db_home.htm, accessed 21 May 2009) [46].
These observations are fully consistent with the high level
of JNK3 that we found in pancreatic islets.
Altogether, JNK1 or JNK2 vs JNK3 deficiencies exert
opposite effects on apoptosis in insulin-secreting cells. The
specific localisation of JNK3 in the nucleus, its recruitment
by cytokines and its role in downregulating c-Jun levels
suggest that JNK3 may play an important role in the
transcriptional control of genes expressed in insulin-
secreting cells.
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